Levocarnitine Market Size, Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, France, Italy, Spain, Japan, China, India, Brazil, Mexico, South Africa, Saudi Arabia), Application Development Potential, Price Trends, Competitive Market Share & Forecast, 2019 – 2025

Levocarnitine Market size is likely to garner a significant growth over the forecast timeframe as increasing incidences of cardiovascular diseases, anorexia, Rett syndrome, thyroid and diabetes is likely to have positive impact on rising demand for levocarnitine for their application in pharmaceutical industry. Increasing geriatric population base across the globe coupled with rising consumer inclination towards health consciousness may foster levocarnitine market growth.
 

Levocarnitine (L-Carnitine) is a molecule required for mammalian energy metabolic activities, which removes toxic acyl chemicals from cell walls to maintain healthy metabolic rate. It is an amino acid which can be naturally synthesized within the body and helps the body to produce energy. It facilitates the transfer of long chain fatty acids across mitochondria for beta oxidation and energy production. Loss of levocarnitine is associated with symptoms of myopathy, cardiomyopathy, and hypoglycemia. In UK, over 10% of total population was diagnosed with high blood pressure in 2017. It is widely given to patients with end stage renal diseases to reduce symptoms of hypotension and intradialytic muscle cramps which may foster levocarnitine market share.
 

Growing inclusion of levocarnitine in food supplements, health drinks, and medicines owing to changing diet patterns, sedentary lifestyle, and increasing awareness towards timely treatment of common disorders may foster market growth. Increasing prevalence of kidney problems such as urinary tract infections and glomerulonephritis (inflammation of the tiny filters in kidneys) may stimulate levocarnitine market share. In Italy, there was over 1,500 of living and deceased kidney transplants in 2017 indicates growing demand for levocarnitine from kidney health application segment.
 

Rising demand for functional foods targeted at specific health issues such as kidney, heart, and musculoskeletal system along with growing demand for sport nutrition from athletes and sports persons may contribute to levocarnitine market growth. Increasing cases of osteoporosis with rising geriatric population in developing countries may foster market share. In Australia, over 900 thousand people were suffering with osteoporosis.  Levocarnitine is widely used in supplements to increase bone mass and decrease the concentration of fat around joints thereby increasing blood circulation, and lubrication may stimulate market growth.
 

Excessive alcohol consumption, smoking habits, and fast-food intake has resulted in imbalance in nutritional requirements which led to increase in various health problems such as obesity, cardiac diseases, and diabetes thereby driving the demand for levocarnitine based supplements. The obesity rates in Asia Pacific between 2010 to 2016 have risen by 58% among adolescents and 33% among adults. Levocarnitine based supplements are widely used to treat obesity as it triggers the metabolic system to burn energy at a faster pace, and aids in breaking of long chain fatty acids which may increase levocarnitine market growth.
 

North America levocarnitine market demand led by the U.S. and Canada should witness a significant growth during forecasted period owing to rising cases of adult and adolescent obesity cases. Increasing consumption of fast food, cheese, and alcohol owing to increase in disposable income, and modern lifestyles leading to several health issues may boost the market share. In Canada domestic wine sales was over USD 5 billion and imports crossed USD 2 billion in 2018. Increasing alcohol intake slows down the metabolic systems which increases the retention of fat cells. Levocarnitine is used in supplements to boost the metabolic and immune system to trigger fat loss naturally.
 

Europe levocarnitine market driven by UK, Germany, France, and Italy may witness moderate growth during forecasted period. Rising cases of renal, arthritis and osteoporosis owing to sedentary lifestyles, rising geriatric population, and increase consumption of fat enhanced diets may trigger the sales of levocarnitine based pharmaceuticals. Levocarnitine based drugs are administered during end stage renal diseases and dialyses which may increase market share.
 

Asia Pacific levocarnitine market demand led by Japan, China, and India may see a significant growth. Increasing cases of kidney problems owing to changing diet patterns, increased alcohol and fast food intake may stimulate market share. Fatty diets slow down the metabolic rate which propagates the stagnation of toxins in cell walls resulting in chronic kidney problems in the long run.
 

Japan has high life expectancy and one of the lowest birth rates globally. According to Forbes magazine, Japan has the lowest population rate in 2018 and by 2065 over 28% of the population will be above the age of 65. Increasing geriatric population in Japan will increase the prevalence of diseases such as Alzheimer’s disease, cardiovascular and osteoporosis issues which may trigger market share. Levocarnitine based pharmaceuticals are administered to induce spatial brain function and regulating metabolic rates thereby driving the demand from their pharmaceutical applications.
 

Global levocarnitine market share is consolidated as the market consist of very few pivotal players. Companies such as Northeast Pharmaceutical Group, Biosynth AG, Alfa Aesar, AIDP, Lonza Group, and Ningbo Honor Chemtech are key players in this market. Increasing number of new entrants owing to potential benefits associated with levocarnitine is projected to impact market demand over the projected period.
 

By Application, 2014-2025 (Tons) (USD Million)

• Supplements
• Pharmaceuticals
• Others

By End-Use, 2014-2025 (Tons) (USD Million)

• Kidney Health
• Bone Health
• Brain Health
• Weight Management Products
• Others

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Poland
  • Russia
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Malaysia
• Latin America
  • Brazil
  • Argentina

• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Company Profiles:

• Northeast Pharmaceutical Group Co., Ltd
• Biosynth AG
• AminoScience LLC
• Alfa Aesar
• AIDP Inc
• Lonza Group Ltd.,
• Spectrum Chemicals and Laboratory Products, Inc
• Wuhan Yuancheng Technology Development Co., Ltd
• Ningbo Honor Chemtech
   

What Information does this report contain?